Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians

David E. Nix, Anup K. Majumdar, Mark J. DiNubile

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Ertapenem, a Group 1 carbapenem, is a once-a-day parenteral β-lactam antibiotic recently licensed in the USA and Europe. Monotherapy with ertapenem dosed as 1 g once a day has been shown to be highly effective in clinical trials for the treatment of complicated infections of skin and skin structures, complicated intra-abdominal infections, community-acquired pneumonia, acute pelvic infections and complicated urinary tract infections. Dosing modifications have not been recommended for adults on the basis of gender, age, weight or liver disease. Presently there are no data regarding the use of ertapenem in children. Dose reductions are indicated for patients with advanced renal insufficiency. Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes; significant drug interactions between ertapenem and drugs handled by these systems are not expected. JAC

Original languageEnglish (US)
JournalJournal of Antimicrobial Chemotherapy
Volume53
Issue numberSUPPL. 2
DOIs
StatePublished - Jun 2004

Fingerprint

Pharmacokinetics
Cytochrome P-450 Enzyme System
Pelvic Infection
Intraabdominal Infections
Lactams
Skin
Carbapenems
P-Glycoprotein
Drug Interactions
Urinary Tract Infections
Renal Insufficiency
Liver Diseases
Pneumonia
ertapenem
Clinical Trials
Anti-Bacterial Agents
Weights and Measures
Infection
Pharmaceutical Preparations
Therapeutics

Keywords

  • Carbapenems
  • Distribution
  • Excretion
  • Metabolism
  • Protein binding
  • Renal insufficiency

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology

Cite this

Pharmacokinetics and pharmacodynamics of ertapenem : An overview for clinicians. / Nix, David E.; Majumdar, Anup K.; DiNubile, Mark J.

In: Journal of Antimicrobial Chemotherapy, Vol. 53, No. SUPPL. 2, 06.2004.

Research output: Contribution to journalArticle

@article{d89c57fef6d549bd883398d47292c5ed,
title = "Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians",
abstract = "Ertapenem, a Group 1 carbapenem, is a once-a-day parenteral β-lactam antibiotic recently licensed in the USA and Europe. Monotherapy with ertapenem dosed as 1 g once a day has been shown to be highly effective in clinical trials for the treatment of complicated infections of skin and skin structures, complicated intra-abdominal infections, community-acquired pneumonia, acute pelvic infections and complicated urinary tract infections. Dosing modifications have not been recommended for adults on the basis of gender, age, weight or liver disease. Presently there are no data regarding the use of ertapenem in children. Dose reductions are indicated for patients with advanced renal insufficiency. Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes; significant drug interactions between ertapenem and drugs handled by these systems are not expected. JAC",
keywords = "Carbapenems, Distribution, Excretion, Metabolism, Protein binding, Renal insufficiency",
author = "Nix, {David E.} and Majumdar, {Anup K.} and DiNubile, {Mark J.}",
year = "2004",
month = "6",
doi = "10.1093/jac/dkh205",
language = "English (US)",
volume = "53",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of ertapenem

T2 - An overview for clinicians

AU - Nix, David E.

AU - Majumdar, Anup K.

AU - DiNubile, Mark J.

PY - 2004/6

Y1 - 2004/6

N2 - Ertapenem, a Group 1 carbapenem, is a once-a-day parenteral β-lactam antibiotic recently licensed in the USA and Europe. Monotherapy with ertapenem dosed as 1 g once a day has been shown to be highly effective in clinical trials for the treatment of complicated infections of skin and skin structures, complicated intra-abdominal infections, community-acquired pneumonia, acute pelvic infections and complicated urinary tract infections. Dosing modifications have not been recommended for adults on the basis of gender, age, weight or liver disease. Presently there are no data regarding the use of ertapenem in children. Dose reductions are indicated for patients with advanced renal insufficiency. Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes; significant drug interactions between ertapenem and drugs handled by these systems are not expected. JAC

AB - Ertapenem, a Group 1 carbapenem, is a once-a-day parenteral β-lactam antibiotic recently licensed in the USA and Europe. Monotherapy with ertapenem dosed as 1 g once a day has been shown to be highly effective in clinical trials for the treatment of complicated infections of skin and skin structures, complicated intra-abdominal infections, community-acquired pneumonia, acute pelvic infections and complicated urinary tract infections. Dosing modifications have not been recommended for adults on the basis of gender, age, weight or liver disease. Presently there are no data regarding the use of ertapenem in children. Dose reductions are indicated for patients with advanced renal insufficiency. Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes; significant drug interactions between ertapenem and drugs handled by these systems are not expected. JAC

KW - Carbapenems

KW - Distribution

KW - Excretion

KW - Metabolism

KW - Protein binding

KW - Renal insufficiency

UR - http://www.scopus.com/inward/record.url?scp=3042637085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042637085&partnerID=8YFLogxK

U2 - 10.1093/jac/dkh205

DO - 10.1093/jac/dkh205

M3 - Article

C2 - 15150180

AN - SCOPUS:3042637085

VL - 53

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - SUPPL. 2

ER -